YKT6

Across TCGA pan-cancer cohorts, YKT6 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated YKT6 data layer compared with 27 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher YKT6 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated YKT6 expression acts as an unfavorable survival marker, although some lineages such as HNSC and UCEC show a favorable association.

LUAD, HNSC, and CCRCC are the cancer types where YKT6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	All	0.661	0.874	.002	19	view →
HNSC	DFS	Median	All	0.865	0.693	.011	10	view →
CCRCC	OS	Median	III,IV	0.485	1.000	.036	9	view →
PDAC	DFS	Tertile	IV	0.203	0.741	.024	7	view →
UCEC	DFS	Median	II,III,IV	0.862	0.538	.048	4	view →
LSCC	DFS	Median	All	0.905	1.000	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

YKT6–LUAD (DFS)

Open the LUAD breakdown →